Tarsal Tunnel Syndrome Drugs Market size is poised to growing at over 5.1% CAGR during the forecast period i.e., between 2024-2036. The growth of the market can be attributed to the increasing prevalence of tarsal tunnel syndrome, backed by high cases of flat feet and sports injuries. Tarsal tunnel syndrome is a nerve dysfunction caused by compression or high pressure in the tarsal tunnel, which is present in the foot of a person. Flat foot, bony growth in feet, tumor near tibial nerve, arthritis, or even diabetes can cause tarsal tunnel syndrome. The rising prevalence of arthritis is a crucial factor estimated to boost the market growth. Between 2018 and 2019, more than 92 million adults were diagnosed with arthritis. Similarly, the incremental incidences of flat foot, with almost 13% of the adults globally suffering from flat foot, is estimated to influence the market growth. In addition to this, the increasing investment in the R&D activities in the medical field, along with rising health awareness amongst the people is estimated to boost the market growth.
Growth Drivers
Challenges
|
Base Year |
2023 |
|
Forecast Year |
2024–2036 |
|
CAGR |
5.1% |
|
Regional Scope |
|
The global tarsal tunnel syndrome drugs market is segmented by treatment into home remedies, physical therapy, surgery and others, out of which, the physical therapy segment is anticipated to hold the notable share over the forecast period on account of better response rate of therapy on the syndrome, easy affordability, and lower risk involved as compared to surgery.
Our in-depth analysis of the global market includes the following segments:
|
By Diagnosis |
|
|
By Distribution Channel |
|
|
By Treatment |
|
On the basis of geographical analysis, the tarsal tunnel syndrome drugs market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. The market in the North America industry is anticipated to hold largest revenue share by 2036, on account of rising prevalence of arthritis, and improving diagnosis facilities. By 2040, an estimated 78 million US adults aged 18 years or older, comprising 26% of the total population in the United States are projected to have doctor-diagnosed arthritis, as per the report by the Centre of Disease Control and Prevention. Moreover, the high healthcare expenditure, and increasing research activities for the development of new drugs are foreseen to boost the tarsal tunnel syndrome drugs market growth.
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?